Market Intelligence

Access the latest earnings reports, market analysis, hot topics, and individual stock insights

Report Categories

View All

Recent Articles

View All
Treasury Yield Surge Challenges RiskFree Status Opens Opportunities in Credit Markets Market Rotation Investors Shift Focus Away from BlueChip Stocks The Mandalorian and Grogu Draws Strong Early Praise Could Reinvigorate Star Wars Franchise Adherex Technologies Expands PEDMARK Focus to Adolescent and Young Adult Market After Record Quarter SpaceX OpenAI Anthropic Could Surpass Berkshire Hathaway on First Trading Day Prediction Markets Suggest NewAmsterdam Pharma NAMS Q1 2026 Earnings Narrowerthanexpected loss as biotech advances pipeline Arvinas ARVN Q1 2026 Earnings Narrower Loss Beats Estimates Amid Pipeline Progress GFR Q1 2026 Earnings Negative EPS Disclosed Amid Limited Data Stock Rises 118 BorgWarner BWA Q1 2026 Earnings EPS Surprises to the Upside Shares Gain Nearly 4 Urban One UONEK Q1 2026 Earnings Loss Per Share of 069 Amid Muted Market Reaction Pentair PNR Holds Steady as Support and Resistance Levels Define Trading Range Xenon Pharmaceuticals XENE Holds Near Support Amid Modest Pullback Title Eastern Company EML Holds Steady at 2126 as Support and Resistance Levels Remain Key Universe Pharmaceuticals UPC Surges 8 Key Support and Resistance Levels to Watch Trump Says Iran Deal Near Strait of Hormuz Could Reopen Tesla AI Stocks Near Buy Points as Futures Open Kardigan Eyes IPO to Advance Cardiology Pipeline Development Alphabets Strategic Bet on Anthropic Offers Indirect AI Exposure Microsofts GitHub Faces Reliability Challenges Amid AI Coding Race Competition Singapore Maintains 2026 GDP Target of 24 Amid Elevated Geopolitical Risks From Iran Conflict RBI Surprises with 25bps Repo Rate Cut to 625 Nomura Says Move Dilutes Policy Framework Novartis Upgrades FullYear Sales and Profit Outlook Analyst Report Highlights Walmarts Resilience Amid Evolving Consumer Landscape Technical Analysis Points to Bullish IntermediateTerm Outlook for Markets Lantheus Holdings Explores Potential 7 Billion Sale Following Curium Pharma Offer